Home Tags ADC

Tag: ADC

Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

New Data Demonstrates Potential for RemeGen’s RC48 in HER2+ Cancers

Results from a robust oncology pipeline, including the latest phase II data of an investigational antibody-drug conjugates (ADC) called RC48 being developed by RemeGen...
Courtesy: Fotolia

The Evolving Market for Antibody-drug Conjugates

The scale of patient demand has fueled an overarching healthcare market need to expand the drug development pipeline to generate more biologics to treat...

Lonza Expands Manufacturing Capacity for ADC Payloads

Lonza, a specialty contract development and manufacturing (CDMO) partner to the biopharma industry, will add new highly potent API (HPAPI) manufacturing suites at its...

Evolution of Antibody-Drug Manufacturing

Antibody-drug Conjugates (ADCs) have evolved since the initial approval of gemtuzumab ozogamicin (Mylotarg®) in 2000, with respect to conjugation, linker and toxin chemistries and...

ADCs – Look Forward to a Potent Future

Antibody-drug conjugation (ADC) technology has been around for several decades but has yet to reach its full potential in terms of clinical success. In...

ADCs – The Dawn of a New Era?

Two decades ago, ADCs were hailed as a major breakthrough, especially in the area of oncology therapeutics. The concept of delivering a potent drug payload directly to the site of the tumor for maximum effect with minimal damage caused to non-cancerous cells was viewed as, if not the Holy Grail of cancer treatment, at least a significant advance towards precision medicine. However, the concept has proved difficult to translate into clinical success.

New Reports Suggests Antibody-drug Conjugates Market to Set Phenomenal Growth in...

A new market research report published in late June by HTF market Intelligence Consulting, suggests that the Antibody-drug conjugates (ADC) Market in China is...

A New Maytansinoid-Payload for Antibody-drug Conjugates Development

Established in 2004, Creative Biolabs, a highly specialized company in advanced antibody biochemistry and engineering, released a novel, high-quality, maytansinoid-payload for the development of...

Are Small-Format Drug Conjugates a Viable ADC Alternative Solid Tumors?

Antibody-drug conjugates or ADCs are complex immunoconjugates. They are designed to selectively deliver a small-molecules cytotoxic payload to cancer cells. Directed to specific tumor...

WuXi Biologics Starts Construction of a State-of-the-Art R&D and Manufacturing Center...

WuXi Biologics, a Hong Kong-listed, open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has started the construction of...

FEATURED